2-aminoimidazole has been researched along with Benign Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bekhradnia, A; Ghanbarimasir, Z; Kardan, M; Morteza-Semnani, K; Rafiei, A; Razzaghi-Asl, N | 1 |
| Balzarini, J; Cammue, BP; De Brucker, K; Delattin, N; Dovgan, B; Dubey, A; Ermolat'ev, D; Fröhlich, M; Girandon, L; Robijns, S; Steenackers, H; Thevissen, K; Van der Eycken, EV; Vanderleyden, J | 1 |
2 other study(ies) available for 2-aminoimidazole and Benign Neoplasms
| Article | Year |
|---|---|
Design, synthesis, biological assessment and molecular docking studies of new 2-aminoimidazole-quinoxaline hybrids as potential anticancer agents.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Humans; Imidazoles; Molecular Docking Simulation; Molecular Structure; Neoplasms; Quinoxalines; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Evaluation of the toxicity of 5-aryl-2-aminoimidazole-based biofilm inhibitors against eukaryotic cell lines, bone cells and the nematode Caenorhabditis elegans.
Topics: Animals; Biofilms; Caenorhabditis elegans; Cell Differentiation; Cell Survival; Cytostatic Agents; Eukaryotic Cells; Humans; Imidazoles; Neoplasms; Osteoblasts; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |